EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Mereo BioPharma Group PLC (MREO) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Mereo BioPharma Group PLC $0.25, price $0.34, upside -25.9%, quality 28 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ADR · ISIN US5894921072

MB Mereo BioPharma Group PLC logo Thin data Sep 23, 2026

Mereo BioPharma Group PLC

MREO · US

Weak valuationQuality is weak on top of the rich price.

!Fair value $0.2500 · Overvalued (−26%)
!Quality 28/100
!Mixed Growth (revenue 5y +4.9 %/yr)
!Low debt · negative free cash flow
!Mixed vs. peers (3/7)
!Narrow moat 5/100
!Evidence only low, so the estimate is less certain
Watch Mereo BioPharma Group PLC ADR for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$4.87 $0.2370 Fair Value $0.2500 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $0.2370 – $4.87 · fair‑value band $0.1700 – $0.3100 · the $0.3375 price screens above the $0.2500 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Mereo BioPharma Group PLC ADR in your weekly email

Every Wednesday you see whether Mereo BioPharma Group PLC ADR is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States.

Show more

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.

Stock analysis

Mereo BioPharma Group PLC ADR (MREO) currently trades at $0.3375, while our model-based Fair Value estimate is $0.2500, implying the stock looks roughly 35.0% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $0.1700 (bear) to $0.3100 (bull), the price of $0.3375 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Mereo BioPharma Group PLC ADR reported revenue of $500K in FY2025 versus $49.2M in FY2021, a compound −68.3%/yr. Reported net income was −$41.9M in FY2025.

Key figures

Market cap $53.8M · P/S ratio 98.8 · EPS (TTM) $−0.1900 · Return on equity −75.9% · Return on assets (EBIT) −54.8% · Operating margin −7,242% · Revenue (TTM) $500K · Free cash flow −$31.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (low confidence).

What moves the price

The share trades about 85% below its 52-week high and 42% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −26%, MREO screens richer than that median.

Fair Value models

Bear $0.1700 Fair Value $0.2500 Bull $0.3100
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.1300 $0.1700 $0.2600 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.1300 $0.1700 $0.2600 54

Open the full fair value analysis →

Notify me when MREO reaches fair value

Put MREO on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 28/100

Of which business quality 30 · Market factors (momentum, volatility) 30

Profitability 0
Margins and returns on capital today
Quality Growth 28
Are margins and returns improving?
Cashflow 5
Earnings quality: real cash, not paper profit
Fin. Strength 72
Balance sheet, leverage, solvency risk
Investment 96
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 33
Price trend over the last 3–12 months (market factor)
52W Momentum 2
Distance to the 52-week high (market factor)
Net Issuance 1
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 8/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−12,258.7% (2020) → −7,651.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

MREO screens 35% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Mereo BioPharma Group PLC ADR with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 654 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 31 · Bottom 25%
Fair Value upside −26% · Above median
Profitability
Return on assets −42% · Bottom 25%
Growth and dividend
Revenue growth 0% · Above median
Balance sheet
Debt / equity 0.11× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.32× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)95 · sector 97
DIVIDEND (yield)0 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $522.38 $574.62 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Mereo BioPharma Group PLC ADR · Fair Value
$0.2500 −35%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Mereo BioPharma Group PLC ADR Fair Value". https://www.fairvalue-calculator.com/stock/MREO

Frequently asked questions

Is Mereo BioPharma Group PLC (MREO) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.2500 versus a price of $0.3375, about −26% upside (overvalued).
What is the fair value of MREO?
Our model-based fair value for Mereo BioPharma Group PLC ADR is $0.2500 (as of Sep 23, 2026), built from audited fundamentals. The current price: $0.3375.
What is the quality score of MREO?
Mereo BioPharma Group PLC ADR has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Mereo BioPharma Group PLC (MREO)?
Our model-based price target is the fair value of $0.2500 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $0.1700, optimistic scenario $0.3100. It is a calculation from audited fundamentals, not an analyst target.
What is the Mereo BioPharma Group PLC ADR stock forecast for 2026?
Our models put fair value at $0.2500, about −26% upside versus a price of $0.3375 (overvalued). Cautious scenario $0.1700, optimistic scenario $0.3100. The calculation is refreshed regularly with new filings.
What is the revenue of Mereo BioPharma Group PLC (MREO)?
Mereo BioPharma Group PLC ADR reported trailing-twelve-month revenue of about $500K (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Mereo BioPharma Group PLC (MREO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Mereo BioPharma Group PLC ADR it is $0.2500 per share (as of Sep 23, 2026), against a price of $0.3375. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Mereo BioPharma Group PLC ADR stock overvalued or undervalued in 2026?
As of Sep 23, 2026, MREO trades above its calculated fair value: price $0.3375, fair value $0.2500, a gap of about −26% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MREO?
No. The price is what the market pays today ($0.3375); the fair value is what the company's own numbers justify ($0.2500). For Mereo BioPharma Group PLC ADR the two are $0.0875 per share apart. That gap is exactly why we show both numbers side by side.
How much is Mereo BioPharma Group PLC ADR worth?
The market values Mereo BioPharma Group PLC ADR at about $53.8M (market capitalisation, as of Sep 23, 2026). Per share that is $0.3375; our models calculate a fair value of $0.2500 per share.
What do the bullish and bearish scenarios say about MREO?
Our models span a range for Mereo BioPharma Group PLC ADR: cautious scenario $0.1700, base $0.2500, optimistic $0.3100 per share (as of Sep 23, 2026, price $0.3375). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Mereo BioPharma Group PLC (MREO)?
Balance-sheet figures for Mereo BioPharma Group PLC ADR (as of Sep 23, 2026): return on equity −75.9%, debt of 0.11 per unit of equity. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is MREO from its 52-week high?
Mereo BioPharma Group PLC ADR trades at $0.3375, about 85% below its 52-week high of $2.31 and 42% above the low of $0.2370 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2500 is for.
Which stocks are comparable to Mereo BioPharma Group PLC ADR?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Mereo BioPharma Group PLC ADR stock attractive at the current price?
The data as of Sep 23, 2026: price $0.3375, calculated fair value $0.2500 (−26%), Quality Score 28/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MREO calculated?
We run Mereo BioPharma Group PLC ADR through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.2500, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Mereo BioPharma Group PLC ADR itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Mereo BioPharma Group PLC (MREO)?
The closing price on Sep 24, 2026 was $0.3375. Our model-based fair value is $0.2500, about −26% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Mereo BioPharma Group PLC ADR right now?
The price sits above even our optimistic bull case ($0.3100). The favourable scenario is already priced in. Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range ($0.1700 to $0.3100) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Mereo BioPharma Group PLC ADR

How large is the market capitalisation of Mereo BioPharma Group PLC (MREO)?
The market capitalisation of Mereo BioPharma Group PLC ADR is $53.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Mereo BioPharma Group PLC (MREO)?
The price-to-sales ratio of Mereo BioPharma Group PLC ADR is 98.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Mereo BioPharma Group PLC (MREO)?
Earnings per share at Mereo BioPharma Group PLC ADR are $−0.1900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Mereo BioPharma Group PLC (MREO)?
The return on equity (ROE) of Mereo BioPharma Group PLC ADR is −75.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Mereo BioPharma Group PLC (MREO)?
On an EBIT basis the return on assets of Mereo BioPharma Group PLC ADR is −54.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Mereo BioPharma Group PLC (MREO)?
The operating margin of Mereo BioPharma Group PLC ADR is −7,242% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Mereo BioPharma Group PLC (MREO) generate?
The free cash flow of Mereo BioPharma Group PLC ADR is −$31.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Mereo BioPharma Group PLC (MREO) hold?
Mereo BioPharma Group PLC ADR holds more cash than debt, $40.8M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Mereo BioPharma Group PLC ADR in the live analysis

One click puts Mereo BioPharma Group PLC ADR on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.